Adalimumab biosimilar - Reliance Life Sciences

Drug Profile

Adalimumab biosimilar - Reliance Life Sciences

Alternative Names: AdaliRel; Adfrar; Adfrar IB; R-TPR-021

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reliance Life Sciences
  • Developer Torrent Pharmaceuticals
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 12 Jan 2016 Launched for Rheumatoid arthritis, Plaque psoriasis, Ulcerative colitis, Psoriatic arthritis and Ankylosing spondylitis in India (SC)
  • 07 Apr 2014 Phase-III clinical trials in Rheumatoid arthritis in India (SC)
  • 29 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top